



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/714,405
Applicant : GOLDSTEIN et al.
Filed : November 17, 2003
TC/A.U. : 1644
Examiner :

Docket No. : 2600-105
Customer No. : 06449

INFORMATION DISCLOSURE STATEMENT

Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450


Dear Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant submits herewith information that the Office may wish to consider in examination of the subject application. Materials submitted for consideration are listed on the attached form PTO-1449. Copies of the US patent documents listed on the accompanying 1449 are not being furnished in accordance with the August 5, 2003 OG notice of waiver of this requirement.

Respectfully submitted,

By _____

George R. Repper
Attorney for Applicants
Registration No. 31,414
ROTHWELL, FIGG, ERNST & MANBECK, p.c.
Suite 800, 1425 K Street, N.W.
Washington, D.C. 20005
Telephone: (202) 783-6040



INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	10/714,405
				Filing Date	November 17, 2003
				First Named Inventor	GOLDSTEIN
				Group Art Unit	1644
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	2600-105

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	1	4,543,340		GOLDSTEIN	04/07/1985
	2	4,444,757		STRAUSSER	04/24/1984
	3	5,652,209		PFLUGFELDER et al.	07/29/1997
	4	6,124,259		DELMAGE et al.	09/26/2000
	5	6,146,630		TSUBOTA et al.	11/14/2000

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee of Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³ Code	Number ⁴	Kind ⁵ (if known)			
	6	WO	96/16983	A1	LA JOLLA CANCER RESEARCH FOUNDATION	06/06/1996	
	7	WO	97/48805	A1	CHILDREN'S MEDICAL CENTER CORPORATION	12/24/1997	
	8	WO	94/11499	A1	MAX-PLANCK- GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.	05/26/1994	
	9	WO	00/06190	A1	THE GOVERNMENT OF THE UNITED STATES OF AMERICA	02/10/2000	
	10	EP	0 124 779	A2	GEORGE WASHINGTON UNIVERSITY	11/14/1984	AB

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code.

⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	10/714,405
				Filing Date	November 17, 2003
				First Named Inventor	GOLDSTEIN
				Group Art Unit	1644
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	2600-105
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
	11	MALINDA, K.M., et al., "Thymosin β 4 stimulates directional migration of human umbilical vein endothelial cells", <i>The FASEB Journal</i> , 1997, vol. 11: 6, 474-481			
	12	SUN, H-Q, et al., " β -Thymosins are not simple actin monomer buffering proteins", <i>The Journal of Biological Chemistry</i> , 1996, vol. 271, no.16, 9223-9230			
	13	NIMNI, M.E., "Polypeptide growth factors: targeted delivery systems," <i>Biomaterials</i> , 1997, vol. 18, no. 18, 1201-1225			
	14	FRANK, S., et al., "Regulation of vascular endothelial growth factor expression in cultured keratinocytes," <i>Journal of Biological Chemistry</i> , 1995, vol. 270, no. :21, 12607-12613			
	15	SABOLINSKI, M.L., et al., "Cultured skin as a 'smart material' for healing wounds: experience in venous ulcers," <i>Biomaterials</i> , 1996, vol. 17, no. 3, pp. 311-320			
	16	HANNAPPEL, E., et al. "Actin-sequestering ability of thymosin β 4, thymosin β 4 fragments, and thymosin β 4-like peptides as assessed by the DNASE I inhibition assay," <i>Biol. Chem.</i> , 1993, vol. 374, 117-122			
	17	MIHELIC, M., et al., "Distribution and biological activity of B-thymosins," <i>Amino Acids</i> , 1994, vol. 6, no. 1, 1-13			
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.